ClinicalTrials.gov
public full text
Public Domain
DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study
The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks. Migraine patients will take DP-VPA or placebo (an inactive look-alike drug) every morning and will have to report any migraine attacks they have during the study's 18-week follow up.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation#829987
- VG081821AC Tablets for Early to Mid-stage Parkinson's Disease#881731
- The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents#1185999
- Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache#1383396
- Topiramate, Amitriptyline Monotherapy and Combination Therapy in Migraine Prophylaxis#861960
Record · ID 1410606
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive